Chemistry:CMV423
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | CMV-423; RPR-111423 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H14ClN3O |
| Molar mass | 275.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection[1] and human herpesvirus 6 (HHV-6) infection.[2][3] The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.[2]
References
- ↑ "2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections". Antiviral Research 55 (3): 413–424. September 2002. doi:10.1016/s0166-3542(02)00074-8. PMID 12206879.
- ↑ 2.0 2.1 "CMV 423". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800010856.
- ↑ "45 - Antivirals against Herpes Viruses". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8th ed.). 2015. pp. 546–562. doi:10.1016/B978-1-4557-4801-3.00045-X. ISBN 978-1-4557-4801-3.
 |  |
